Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/08—Antiseborrheics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/28—Antiandrogens

Definitions

• This invention pertains to methods for prevention and treatment of inflammatory skin conditions.
• Inflammatory skin conditions can have significant physical and psychological impacts on the quality of life of those afflicted.
• Inflammatory skin conditions include inflammatory skin disorders such as acne vulgaris, allergic or atopic dermatitis, alopecia areata, androgenetic alopecia, dandruff, dermatitis herpetiformis, discoid lupus erythematosus, pemphigus, primary cicatricial alopecia, psoriasis, and seborrheic dermatitis.
• Inflammatory skin conditions can also include skin inflammation due to exposure to excessive thermal and ultraviolet radiation. Methods for preventing and or treating such inflammatory skin conditions are desirable.
• One aspect of the invention provides a method of preventing and or treating inflammatory skin conditions comprising topically administering a therapeutically effective amount of aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), or a combination thereof.
• ATA aurin tricarboxylic acid
• AQA aurin quadracarboxylic acid
• AHA aurin hexacarboxylic acid
• the combination may comprise 60 to 90% AHA, 10 to 30% AQA, and 1 to 20% AHA, or comprise 78% AHA, 15% AQA, and 7% AHA.
• the condition may be acne vulgaris, allergic or atopic dermatitis, alopecia areata, androgenetic alopecia, dandruff, dermatitis herpetiformis, discoid lupus erythematosus, pemphigus, primary cicatricial alopecia, psoriasis, seborrheic dermatitis, thermal or ultraviolet burns, or any condition affecting the skin involving abnormal activation of complement.
• the therapeutic agent may be formulated in a hair care preparation, skin care preparation, or a pharmaceutical composition at a concentration of 0.1 to 100 mg/mL.
• the hair care preparation, skin care preparation or pharmaceutical composition may be a spray, gel, cream, lotion, stick, ointment, scrub, soap bar, tonic, roll-on formulation, sunscreen, shampoo or mousse.
• Figures 1A-1D are scanned images illustrating the effect of an embodiment of the invention on androgenetic alopecia.
• Figures 1A and 1C show affected scalps of male patients pre-treatment
• Figures IB and ID show the respective scalps of the male patients post-treatment.
• Figures 2A and 2B are scanned images illustrating the effect of an embodiment of the invention on acne vulgaris.
• Figure 2A shows an affected facial area of a male patient pre- treatment
• Figure 2B shows the same area of the male patient post-treatment.
• Figures 3A and 3B are scanned images illustrating the effect of an embodiment of the invention on sunburns.
• Figure 3A shows a sunlight exposed area of a female patient pre- treatment
• Figure 3B shows the same area of the female patient post-treatment.
• Figures 4A and 4B are scanned images illustrating the effect of an embodiment of the invention on allergic or atopic dermatitis.
• Figure 4A shows an affected area of the abdomen of a male patient pre-treatment
• Figure 4B shows the same area of the male patient post-treatment.
• the invention relate to methods of preventing and or treating inflammatory skin conditions by topical application of aurin tricarboxylic acid (ATA), quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA) and/or combinations thereof (AT AC) having a molecular weight less than lkDa (collectively, "low molecular weight ATA compounds”)-
• ATA aurin tricarboxylic acid
• AQA quadracarboxylic acid
• AHA aurin hexacarboxylic acid
• AT AC aurin hexacarboxylic acid
• AT AC aurin hexacarboxylic acid
• AT AC aurin hexacarboxylic acid
• AT AC aurin hexacarboxylic acid
• AT AC aurin hexacarboxylic acid
• AT AC aurin hexacarboxylic acid
• AT AC aurin
• ATA has an approximate molecular weight of 422.
• AQA has an approximate molecular weight of 573.
• AHA has an approximate molecular weight of 857.
• ATA, AQA, and AHA are low molecular weight components of crude synthetic "ATA" or commercial "ATA" (e.g. aluminon), and can for example be obtained from these sources by passing them through a 1 kDa filter.
• ATAC comprises a mixture of ATA, AQA and AHA and may in example embodiments be comprised of approximately 78% AHA, 15% AQA, and 7% AHA. In some embodiments, ATAC may be comprised of 60 to 90% AHA, 10 to 30% AQA, and 1 to 20% AHA.
• low molecular weight ATA compounds are topically administered to patients with inflammatory skin conditions such as acne vulgaris, allergic dermatitis, alopecia areata, androgenetic alopecia, atopic dermatitis, dandruff, dermatitis herpetiformis, discoid lupus erythematosus, pemphigus, primary cicatricial alopecia, psoriasis, seborrheic dermatitis, or ultraviolet or thermal burns.
• inflammatory skin conditions such as acne vulgaris, allergic dermatitis, alopecia areata, androgenetic alopecia, atopic dermatitis, dandruff, dermatitis herpetiformis, discoid lupus erythematosus, pemphigus, primary cicatricial alopecia, psoriasis, seborrheic dermatitis, or ultraviolet or thermal burns.
• one or more of the low molecular weight ATA compounds may administered in the form of a skin care preparation, hair care preparation or a pharmaceutical composition formulated for application to affected areas of the skin or scalp of a patient.
• Such preparations or compositions may for example be formulated as a spray, gel, cream, lotion, stick, ointment, scrub, soap bar, tonic, roll-on formulation, sunscreen, shampoo or mousse wherein the one or more low molecular weight ATA compounds, or a pharmaceutically acceptable salt or solvate thereof, is provided in a therapeutically effective amount together with at least one carrier so as to be capable of exerting a therapeutic effect on an inflammatory skin conditions on the patient's skin or scalp.
• the one or more of the low molecular weight ATA compounds may be provided in such preparations or compositions at a concentration of 0.1 to 100 mg/mL, or 0.1 to 10 mg/mL, or 0.5 to 5 mg/mL, and may be topically applied one to five times daily for example.
• the preparations or compositions may also include one or more of surfactants, propellants, co-solvents, gelling agent, and other ingredients suitable for use in skin or hair care preparations of the type known in the art, such as petrolatum, waxes, oils plasticizers, preservatives, fragrances and the like.
• the preparations or compositions may be applied to the skin or scalp of a patient using bottles or containers (e.g. shampoos), tubes (e.g. gels, creams, ointments, lotions), pressurized canisters (e.g. sprays, mousses), pads, sticks, or "roll-on” applicators (e.g. gels, ointments).
• the preparations or compositions may be formulated to form a film over the skin or scalp, thus allowing controlled release and penetration of the one or more of the low molecular weight ATA compounds into the affected areas.
• one or more of the low molecular weight ATA compounds may be provided at a concentration of 0.1 to 100 mg/mL, or 0.1 to 10 mg/mL, or 0.5 to 5 mg/mL, in an aqueous shampoo base comprising the surfactants sodium lauryl sulfate and cocamidopropyl betaine, for application to the scalp.
• one or more of the low molecular weight ATA compounds may be provided at a concentration of 0.1 to 100 mg/mL, or 0.1 to 10 mg/mL, or 0.5 to 5 mg/mL, in an ointment comprising glycerin, for application to the skin or scalp.
• one or more of the low molecular weight ATA compounds may be provided at a concentration of 0.1 to 100 mg/mL, or 0.1 to 10 mg/mL, or 0.5 to 5 mg/mL, in a gel comprising aloe vera, for application to the skin or scalp.
• one or more of the low molecular weight ATA compounds may be dissolved at a concentration of 0.1 to 100 mg/mL, or 0.1 to 10 mg/mL, or 0.5 to 5 mg/mL, in water and applied as a spray or other means to the affected skin or scalp area.
• one or more of the low molecular weight ATA compounds may be provided at a concentration of 0.1 to 100 mg/mL, or 0.1 to 10 mg/mL, or 0.5 to 5 mg/mL, in a sunscreen formulation comprising one or more known active sunscreen ingredients.
• Figure 1 A shows the scalp of a male patient suffering from androgenetic alopecia.
• Figure IB shows new hair beginning to grow in following 23 days of topical application of an aqueous solution of 1 mg/mL ATAC (approximately 78% AHA, 15% AQA, and 7% AHA) three times per day.
• Figure 1C shows the scalp of another male patient suffering from androgenetic alopecia.
• Figure ID shows new hair growth 2 months following similar application of ATAC.
• Figure 2A shows a facial area of a young man suffering from acne vulgaris.
• Figure 2B shows the same area following 7 days of topical application of an aqueous solution of 1 mg/mL ATAC (approximately 78% AHA, 15% AQA, and 7% AHA) three times per day.
• ATAC aqueous solution of 1 mg/mL ATAC
• a common, known treatment for acne vulgaris is the antioxidant benzoyl peroxide, which has the drawback of increasing sensitivity to the sun.
• the present invention is not only effective against acne vulgaris but against sunburn as well, providing a distinct advantage over the commonly utilized benzyol peroxide.
• Example 3 Thermal and ultraviolet burn
• Figure 3A shows an area of sunburn in a woman with sensitive skin that had been briefly exposed to sunlight.
• Figure 3B shows the same area 25 hours following topical application of an ointment of 1 mg/mL AT AC (approximately 78% AHA, 15% AQA, and 7% AHA) mixed with glycerin. The pain upon touching disappeared almost immediately after application of the AT AC ointment. Redness also diminished over the next several hours.
• AT AC approximately 78% AHA, 15% AQA, and 7% AHA
• Figure 4A shows an area of the abdomen in a man diagnosed with allergic or atopic dermatitis.
• Figure 4B shows the same area following topical application of 1 mg/mL AT AC (approximately 78% AHA, 15% AQA, and 7% AHA). Redness decreased and itching disappeared within a few minutes of the application.
• Alopecia areata is a condition in which there is hair loss, usually from the scalp. It is characterized by an inflammatory response involving lymphocytic infiltration around vulnerable follicles, so that the hair growth disappears. By inhibiting harmful complement activation, low molecular weight ATA compounds will be effective therapeutics. Topically apply a composition comprising 0.1 to 100 mg/mL ATA, AQA, AHA or ATAC to affected areas of the scalp of a patient suffering from alopecia areata for a period of 1 day to 6 months, from one to five times daily.
• Dandruff and seborrheic dermatitis are conditions involving excessive loss of corneocytes from the outer layer of the epidermis. These conditions are characterized by increased levels of inflammatory markers. By inhibiting harmful complement activation, low molecular weight ATA compounds will be effective therapeutics. Topically apply a composition comprising 0.1 to 100 mg/mL ATA, AQA, AHA or ATAC to affected areas of the skin or scalp of a patient suffering from dandruff or seborrheic dermatitis for a period of 1 day to 6 months, from one to five times daily.
• Dermatitis herpetiformis is characterized by an extremely itchy rash, caused by immune attack against the protein epidermal transglutaminase. By inhibiting harmful complement activation, low molecular weight ATA compounds will be effective therapeutics. Topically apply a composition comprising 0.1 to 100 mg/mL ATA, AQA, AHA or AT AC to affected areas of the skin a patient suffering from dermatitis herpetiformis for a period of 1 day to 6 months, from one to five times daily.
• ATA 0.1 to 100 mg/mL ATA, AQA, AHA or AT AC
• Discoid lupus erythematosis is an autoimmune disorder which is highly exacerbated by sunlight.
• Known treatment is with topical steroids, indicative of the effectiveness of immune blockade.
• By inhibiting harmful complement activation, low molecular weight ATA compounds will be effective therapeutics.
• Topically apply a composition comprising 0.1 to 100 mg/mL ATA, AQA, AHA or AT AC to affected areas of the skin a patient suffering from discoid lupus erythematosis for a period of 1 day to 6 months, from one to five times daily.
• Pemphigus is a potentially fatal disorder where there is an autoimmune attack against desmoglien, the adhesive protein which forms the attachment of adjacent epidermal cells.
• ATA compounds By inhibiting harmful complement activation, low molecular weight ATA compounds will be effective therapeutics.
• Topically apply a composition comprising 0.1 to 100 mg/mL ATA, AQA, AHA or ATAC to affected areas of the skin a patient suffering from pemphigus for a period of 1 day to 6 months, from one to five times daily.
• Example 6 Primary cicatricial alopecia is a skin disorder in which epithelial hair follicle stem cells are damaged or destroyed by inflammation. By inhibiting harmful complement activation, low molecular weight ATA compounds will be effective therapeutics. Topically apply a composition comprising 0.1 to 100 mg/mL ATA, AQA, AHA or ATAC to affected areas of the scalp of a patient suffering from primary cicatricial alopecia for a period of 1 day to 6 months, from one to five times daily.
• Example 7 Psoriasis
• Psoriasis is a common skin condition which is characterized by an overactive immune response. By inhibiting harmful complement activation, low molecular weight ATA compounds will be effective therapeutics. Topically apply a composition comprising 0.1 to 100 mg/mL ATA, AQA, AHA or AT AC to affected areas of the skin a patient suffering from psoriasis for a period of 1 day to 6 months, from one to five times daily.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Botany (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Birds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Emergency Medicine (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=50881631

Family Applications (1)

Country Status (7)

Cited By (2)

Families Citing this family (1)

Citations (6)

Family Cites Families (6)

• 2012
  • 2012-12-06 US US13/694,484 patent/US8877808B2/en active Active
• 2013
  • 2013-06-21 EP EP13860898.9A patent/EP2928460B1/en not_active Not-in-force
  • 2013-06-21 CA CA2893966A patent/CA2893966C/en active Active
  • 2013-06-21 CN CN201380069919.XA patent/CN104902886A/zh active Pending
  • 2013-06-21 KR KR1020157017948A patent/KR20150090920A/ko not_active Withdrawn
  • 2013-06-21 JP JP2015545609A patent/JP2016501236A/ja active Pending
  • 2013-06-21 WO PCT/CA2013/050488 patent/WO2014085920A1/en active Application Filing

Patent Citations (6)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events